Cystic Fibrosis Therapeutics Market, Size, Global Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Company Analysis
Cystic Fibrosis Therapeutics Market Outlook
Global Cystic Fibrosis Therapeutics Market size will reach US$ 24.35 Billion by 2028 according to Renub Research. Cystic Fibrosis is an ongoing genetic disease that affects the lungs and other body systems (Pancreas, Liver, and Kidney) and for which there is currently no cure. It mainly affects the digestive and respiratory systems in children and young adults. About half of the population with cystic fibrosis will live past 40. It can cause problems with digestion and breathing from childhood age.
Over a decade, the lungs become increasingly damaged and may eventually stop working correctly. The primary target organs in cystic fibrosis are the sweat glands, the lungs, and the gastrointestinal tract, particularly the pancreas. Although clinically the least serious problem, increased sodium and chloride concentration in sweat is the undisputed hallmark of cystic fibrosis. The main symptoms of cystic fibrosis include chest infections, difficulty putting on weight, wet-sounding coughs, and others. Physical therapy is used to treat cystic fibrosis, which helps reduce mucus from the lungs, Provide complete nutrition, etc.
The outlook for cystic fibrosis has improved considerably in recent five years due to advancements in RD of treatment, although most people with cystic fibrosis will have shorter-than-average life assurance. According to Cystic Fibrosis Patient Registry, more than 30,000 people are currently suffering from this condition in the U.S., while more than 70,000 people are suffering from Cystic Fibrosis across the globe. In addition to this, more than approximately 1000 new cases of the disease are diagnosed every year.
Worldwide Cystic Fibrosis Market is expected to grow at a CAGR of 14.40% throughout the Forecast Period.
Rising spending on R&D research and other technological advancements in these therapeutic areas will open a new source of growth for industry participants. However, the higher cost of therapy, and several adverse effects of currently available drugs, such as liver problems, upper respiratory tract infection, chest pain, and increased blood pressure, among others, will restrain the industry growth. The Global Cystic Fibrosis industry was valued at US$ 10.86 Billion in 2022.
By Route of Administration: Inhale market will capture maximum share in the forecast Period
Based on the Route of Administration, The Global Cystic Fibrosis market has been divided into two types oral and inhaled. The Inhale holds significant share due to their use leading to high drug levels within the airways, with lean systemic effects, and High-quality devices providing safe and convenient antibiotic and mucolytic therapy for individuals with Cystic Fibrosis dominate the market.
Medication Treatment Method holds Largest Market
Based on Treatment, Medication captured the largest share during the forecast period due to antibiotics to prevent and treat chest infections, to make the mucus easier to cough up, the lungs thinner, and medicines to reduce inflammation and widen the airways. In addition, other factors such as rising demand and awareness about advance help stimulate the industry's expansion and significantly affect market share. The market has been categorized into Medication, Devices, and Other Treatments. Devices also hold the significant market revenue as the most commonly used pieces of equipment for CF treatments are compressors, nebulizers, and airway clearance devices. These are readily available in the market and convenient for patients.
By Test Type: Pulmonary Function Test Type holds the Significant Market
On the Test Type segment, the Global Cystic Fibrosis Therapeutics Market has been differentiated into Pulmonary Function, Sweat, IRT, Fecal, and Genetic. The Pulmonary Function Test holds the most significant revenue in 2022 due to the tests measuring lung volume, capacity, rates of flow, and gas exchange. This information can help healthcare providers diagnose and decide the treatment of certain lung disorders has significantly dominated the segment.
By Distribution Channels: Hospitals holds the Maximum Revenue
By Distribution Channels, Hospitals hold the maximum revenue due to the growing demand for the disease and the need for the right diagnosis and follow-up treatments under medical supervision. This leads to an increase in patient hospital visits, moving the growth of the hospital segment. Moreover, earnings generated by hospital pharmacies are proportionately high because infected people commonly visit nearby hospitals for doctor's prescription medicines and appointments. Therefore, the market is segmented into Hospitals, Retail Pharmacies, and Others.
CFTR Modulators Drug Class will gain the maximum revenue in upcoming years
Subjected to drug class, the Global Cystic Fibrosis industry has been grouped into Pancreatic Enzyme Supplements Drug, Mucolytic Drugs, Bronchodilators Drug, and CFTR Modulators Drug. The CFTR Modulators Drug holds the maximum revenue because CFTR modulator drugs are novel-specialized therapies that enhance the functional expression of CFTR mutants and have been approved for clinical use for individuals with specific CF genotypes. Highly effective CFTR modulator drugs are expected to modify the disease course for most individuals with CF profoundly. In addition, advanced experimental approaches have been established to accelerate the development of novel modulators, effectively boosting the Cystic Fibrosis Therapeutics Market.
North America will capture the maximum market in forecast period
By Region, the Global Cystic Fibrosis Market has been divided into North America, Latin America, Europe, Asia Pacific, and Others. However, North America dominated the market share due to demand from the increasing occurrence of cystic fibrosis and the accessibility of several treatment options in the Region. Moreover, rising government initiative such as increasing funding for innovations and R&D projects on cystic fibrosis drug drives the industry revenue. For instance, the North American Cystic Fibrosis Conference (NACFC gives an educational forum for cystic fibrosis specialists to share developments in R&D related to cystic fibrosis therapeutics.
In addition, other factors, such as the presence of foremost market leaders, reimbursements, and well-established healthcare infrastructure, will propel the North American market demand over the forecast timeframe.
Key Company Insight
Some of the primary key players in the Global Cystic Fibrosis Therapeutics Market include Vertex Pharmaceuticals, Abbvie Inc., Novartis Ag, Gilead Sciences, Viatris INC, Pfizer, and AstraZeneca.
In August 2021, Sanofi signed an agreement to acquire Translate Bio, all outstanding shares, for $3.2 billion. Translate Bio has cystic fibrosis and other rare pulmonary diseases in his pipeline.
In Nov 2021, Eloxx Pharmaceuticals announced the monotherapy arms product pipeline of its Phase 2 clinical trial of ELX-02 in cystic fibrosis (CF) Class 1.
Renub Research report titled “Cystic Fibrosis Therapeutics Market, Global Forecast by Route of Administration (Oral and Inhale), Treatment (Medication, Devices, Other Treatment), Test Type (Plumonary Function, Sweat Colories, IRT Test, Faceal Tests and Genetic Tests), Distribution (Hospital, Retail Pharmacies and Others), Drug Class (Pancreatic Enzyme Supplements, Mucolytics, Bronchodilators and CFTR Modulators) Regions (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Company Analysis (Vertex Pharmaceuticals, Abbvie Inc., Novartis Ag, Gilead Sciences, Viatris INC, Pfizer and Astrazeneca,)” Provides a detailed analysis of Cystic Fibrosis Therapeutics Market.
Route of Administration - Cystic Fibrosis Therapeutics Market Analysis have been Covered from 2 Viewpoints
1. Oral
2. Inhale
Treatment - Cystic Fibrosis Therapeutics Market Analysis have been Covered from 3 Viewpoints
1. Medication
2. Devices
3. Other Treatment
Test Type - Cystic Fibrosis Therapeutics Market Analysis have been Covered from 5 Viewpoints
1. Plumonary Function
2. Sweat Calories
3. IRT Test
4. Faceal Tests
5. Genetic Tests
Distribution - Cystic Fibrosis Therapeutics Market Analysis have been Covered from 3 Viewpoints
1. Hospital
2. Retail Pharmacies
3. Others
Drug Class - Cystic Fibrosis Therapeutics Market Analysis have been Covered from 4 Viewpoints
1. Pancreatic Enzyme Supplements
2. Mucolytics
3. Bronchodilators
4. CFTR Modulators
Region - Cystic Fibrosis Therapeutics Market Analysis have been Covered from 5 Viewpoints
1. North America
2. Europe
3. Asia Pacific
4. Latin America
5. Middle East & Africa
All companies have been covered from 3 viewpoints:
• Overviews
• Recent Developments
• Revenues
Company
1. Vertex Pharmaceuticals
2. Abbvie Inc.
3. Novartis Ag
4. Gilead Sciences
5. Viatris INC
6. Pfizer
7. Astrazeneca
Report Details:
| Report Features | Details |
| Base Year | 2022 |
| Historical Period | 2017 - 2022 |
| Forecast Period | 2023 - 2028 |
| Market | US$ Billion |
| Segment Covered | Route of Administration, Treatment, Test Type, Distribution, Drug Class, Region |
| Regions Covered | North America, Europe, Asia Pacific, Latin America and Middle East & Africa |
| Companies Covered | Vertex Pharmaceuticals, Abbvie Inc., Novartis Ag, Gilead Sciences, Viatris INC, Pfizer and Astrazeneca |
| Customization Scope | 20% Free Customization |
| Post-Sale Analyst Support | 1 Year (52 Weeks) |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on request) |
1. Introduction
2. Research & Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Global Cystic Fibrosis Therapeutics Market
6. Market Share – Global Cystic Fibrosis Therapeutics Market
6.1 By Route of Administration
6.2 By Treatment Method
6.3 By Test Type
6.4 By Distribution Channels
6.5 By Drug Class
6.6 By Region
7. Route of Administration – Global Cystic Fibrosis Therapeutics Market
7.1 Oral
7.2 Inhale
8. Treatment Method – Global Cystic Fibrosis Therapeutics Market
8.1 Medication
8.2 Devices
8.3 Other Treatment
9. Test Type – Global Cystic Fibrosis Therapeutics Market
9.1 Pulmonary Function Test
9.2 Sweat Test
9.3 IRT Test
9.4 Fecal Tests
9.5 Genetic Tests
10. Distribution Channels – Global Cystic Fibrosis Therapeutics Market
10.1 Hospitals
10.2 Retail Pharmacies
10.3 Others
11. Drug Class – Global Cystic Fibrosis Therapeutics Market
11.1 Pancreatic Enzyme Supplements Drug
11.2 Mucolytics Drug
11.3 Bronchodilators Drug
11.4 CFTR Modulators Drug
12. Region – Global Cystic Fibrosis Therapeutics Market
12.1 North America
12.2 Europe
12.3 Asia Pacific
12.4 Latin America
12.5 Middle East & Africa
13. Company Insights
13.1 Vertex Pharmaceuticals
13.1.1 Overview
13.1.2 Recent Development
13.1.3 Revenue
13.2 Abbvie Inc.
13.2.1 Overview
13.2.2 Recent Development
13.2.3 Revenue
13.3 Novartis Ag
13.3.1 Overview
13.3.2 Recent Development
13.3.3 Revenue
13.4 Gilead Sciences
13.4.1 Overview
13.4.2 Recent Development
13.4.3 Revenue
13.5 Viatris INC
13.5.1 Overview
13.5.2 Recent Development
13.5.3 Revenue
13.6 Pfizer
13.6.1 Overview
13.6.2 Recent Development
13.6.3 Revenue
13.7 Astrazeneca
13.7.1 Overview
13.7.2 Recent Development
13.7.3 Revenue
List of Figures:
Figure-01: Global – Cystic Fibrosis Therapeutics Market (Billion US$), 2016 – 2022
Figure-02: Global – Forecast for Cystic Fibrosis Therapeutics Market (Billion US$), 2023 – 2028
Figure-03: Route of Administration – Oral Market (Million US$), 2016 – 2022
Figure-04: Route of Administration – Forecast for Oral Market (Million US$), 2023 – 2028
Figure-05: Route of Administration – Inhale Market (Million US$), 2016 – 2022
Figure-06: Route of Administration – Forecast for Inhale Market (Million US$), 2023 – 2028
Figure-07: Treatment Method – Medication Market (Million US$), 2016 – 2022
Figure-08: Treatment Method – Forecast for Medication Market (Million US$), 2023 – 2028
Figure-09: Treatment Method – Devices Market (Million US$), 2016 – 2022
Figure-10: Treatment Method – Forecast for Devices Market (Million US$), 2023 – 2028
Figure-11: Treatment Method – Other Treatment Market (Million US$), 2016 – 2022
Figure-12: Treatment Method – Forecast for Other Treatment Market (Million US$), 2023 – 2028
Figure-13: Test Type – Pulmonary Function Test Market (Million US$), 2016 – 2022
Figure-14: Test Type – Forecast for Pulmonary Function Test Market (Million US$), 2023 – 2028
Figure-15: Test Type – Sweat Test Market (Million US$), 2016 – 2022
Figure-16: Test Type – Forecast for Sweat Test Market (Million US$), 2023 – 2028
Figure-17: Test Type – IRT Test Market (Million US$), 2016 – 2022
Figure-18: Test Type – Forecast for IRT Test Market (Million US$), 2023 – 2028
Figure-19: Test Type – Fecal Tests Market (Million US$), 2016 – 2022
Figure-20: Test Type – Forecast for Fecal Tests Market (Million US$), 2023 – 2028
Figure-21: Test Type – Genetic Tests Market (Million US$), 2016 – 2022
Figure-22: Test Type – Forecast for Genetic Tests Market (Million US$), 2023 – 2028
Figure-23: Distribution Channels – Hospitals Market (Million US$), 2016 – 2022
Figure-24: Distribution Channels – Forecast for Hospitals Market (Million US$), 2023 – 2028
Figure-25: Distribution Channels – Retail Pharmacies Market (Million US$), 2016 – 2022
Figure-26: Distribution Channels – Forecast for Retail Pharmacies Market (Million US$), 2023 – 2028
Figure-27: Distribution Channels – Others Market (Million US$), 2016 – 2022
Figure-28: Distribution Channels – Forecast for Others Market (Million US$), 2023 – 2028
Figure-29: Drug Class – Pancreatic Enzyme Supplements Drug Market (Million US$), 2016 – 2022
Figure-30: Drug Class – Forecast for Pancreatic Enzyme Supplements Drug Market (Million US$), 2023 – 2028
Figure-31: Drug Class – Mucolytics Drug Market (Million US$), 2016 – 2022
Figure-32: Drug Class – Forecast for Mucolytics Drug Market (Million US$), 2023 – 2028
Figure-33: Drug Class – Bronchodilators Drug Market (Million US$), 2016 – 2022
Figure-34: Drug Class – Forecast for Bronchodilators Drug Market (Million US$), 2023 – 2028
Figure-35: Drug Class – CFTR Modulators Drug Market (Million US$), 2016 – 2022
Figure-36: Drug Class – Forecast for CFTR Modulators Drug Market (Million US$), 2023 – 2028
Figure-37: North America – Cystic Fibrosis Therapeutics Market (Million US$), 2016 – 2022
Figure-38: North America – Forecast for Cystic Fibrosis Therapeutics Market (Million US$), 2023 – 2028
Figure-39: Europe – Cystic Fibrosis Therapeutics Market (Million US$), 2016 – 2022
Figure-40: Europe – Forecast for Cystic Fibrosis Therapeutics Market (Million US$), 2023 – 2028
Figure-41: Asia Pacific – Cystic Fibrosis Therapeutics Market (Million US$), 2016 – 2022
Figure-42: Asia Pacific – Forecast for Cystic Fibrosis Therapeutics Market (Million US$), 2023 – 2028
Figure-43: Latin America – Cystic Fibrosis Therapeutics Market (Million US$), 2016 – 2022
Figure-44: Latin America – Forecast for Cystic Fibrosis Therapeutics Market (Million US$), 2023 – 2028
Figure-45: Middle East & Africa – Cystic Fibrosis Therapeutics Market (Million US$), 2016 – 2022
Figure-46: Middle East & Africa – Forecast for Cystic Fibrosis Therapeutics Market (Million US$), 2023 – 2028
Figure-47: Vertex Pharmaceuticals – Global Revenue (Billion US$), 2016 – 2022
Figure-48: Vertex Pharmaceuticals – Forecast for Global Revenue (Billion US$), 2023 – 2028
Figure-49: Abbvie Inc. – Global Revenue (Billion US$), 2016 – 2022
Figure-50: Abbvie Inc. – Forecast for Global Revenue (Billion US$), 2023 – 2028
Figure-51: Novartis Ag – Global Revenue (Billion US$), 2016 – 2022
Figure-52: Novartis Ag – Forecast for Global Revenue (Billion US$), 2023 – 2028
Figure-53: Gilead Sciences – Global Revenue (Billion US$), 2016 – 2022
Figure-54: Gilead Sciences – Forecast for Global Revenue (Billion US$), 2023 – 2028
Figure-55: Viatris INC – Global Revenue (Billion US$), 2016 – 2022
Figure-56: Viatris INC – Forecast for Global Revenue (Billion US$), 2023 – 2028
Figure-57: Pfizer – Global Revenue (Billion US$), 2016 – 2022
Figure-58: Pfizer – Forecast for Global Revenue (Billion US$), 2023 – 2028
Figure-59: Astrazeneca – Global Revenue (Billion US$), 2016 – 2022
Figure-60: Astrazeneca – Forecast for Global Revenue (Billion US$), 2023 – 2028
List of Tables:
Table-01: Global – Cystic Fibrosis Therapeutics Market Share by Route of Administration (Percent), 2016 – 2022
Table-02: Global – Forecast for Cystic Fibrosis Therapeutics Market Share by Route of Administration (Percent), 2023 – 2028
Table-03: Global – Cystic Fibrosis Therapeutics Market Share by Treatment Method (Percent), 2016 – 2022
Table-04: Global – Forecast for Cystic Fibrosis Therapeutics Market Share by Treatment Method (Percent), 2023 – 2028
Table-05: Global – Cystic Fibrosis Therapeutics Market Share by Test Type (Percent), 2016 – 2022
Table-06: Global – Forecast for Cystic Fibrosis Therapeutics Market Share by Test Type (Percent), 2023 – 2028
Table-07: Global – Cystic Fibrosis Therapeutics Market Share by Distribution Channels (Percent), 2016 – 2022
Table-08: Global – Forecast for Cystic Fibrosis Therapeutics Market Share by Distribution Channels (Percent), 2023 – 2028
Table-09: Global – Cystic Fibrosis Therapeutics Market Share by Drug Class (Percent), 2016 – 2022
Table-10: Global – Forecast for Cystic Fibrosis Therapeutics Market Share by Drug Class (Percent), 2023 – 2028
Table-11: Global – Cystic Fibrosis Therapeutics Market Share by Region (Percent), 2016 – 2022
Table-12: Global – Forecast for Cystic Fibrosis Therapeutics Market Share by Regions(Percent), 2023 – 2028
Reach out to us
Call us on
USA: +1-678-302-0700
INDIA: +91-120-421-9822
Drop us an email at
info@renub.com